<div id="readability-page-1"><p>Analyst Yun Zhong of Wedbush maintained a Buy rating on CAMP4 Therapeutics Corporation, with a price target of $8.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Yun Zhong has given his Buy rating due to a combination of factors, including CAMP4’s steady advancement of CMP-002 toward a first global Phase 1/2 trial in SYNGAP1-related disorders in the second half of 2026 and the relatively low perceived regulatory risk around the initial Australian filing. He also highlights that a successful regulatory approval would unlock a second $50M tranche from the previously announced $100M private placement, reinforcing the company’s already solid cash position of $99.2M and runway guidance into 2028.</p> <p>In addition, Zhong views the planned placebo-controlled trial, with multiple dosing cohorts and seizure reduction as a key efficacy measure, as a meaningful value inflection point that could validate CAMP4’s broader RNA-based platform in severe genetic diseases. He further notes that the collaboration with the CURE SYNGAP1 foundation and access to natural history data should optimize study design, while the absence of approved therapies and the severity of the disease may prompt regulatory flexibility, creating an attractive risk‑reward profile that supports his Buy recommendation.</p> <p>In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $12.00 price target.</p> </div>

CAMP

LABU

SBIO

<p>Analyst Yun Zhong of Wedbush has reaffirmed a Buy rating on CAMP4 Therapeutics with a price target of $8.00, citing the advancement of CMP-002 towards a Phase 1/2 trial in SYNGAP1-related disorders by 2026. The company has a solid cash position of $99.2M, extending its runway into 2028. Zhong highlights the potential for regulatory approval to unlock additional funding and views the upcoming trial as a significant value inflection point. Piper Sandler also maintains a Buy rating with a $12.00 price target.</p>

Tip Ranks

CAMP4 Therapeutics

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ALPS Medical Breakthrough

Piper Sandler Cos

Buy Rating Reaffirmed on CAMP4 as CMP-002 Advances Toward 2026 SYNGAP1 Trial and Strong Cash Runway Extends Into 2028